Phathom Pharmaceuticals (PHAT) has filed a preliminary prospectus for a 7.9M-share IPO at $18 – 20 per share.
The Buffalo Grove, IL-based biopharmaceutical firm
develops treatments for gastrointestinal diseases. Lead candidate is
vonoprazan, a potassium-competitive acid blocker (P-CAB), for the
potential treatment of gastroesophageal reflux disease (GERD), H. pylori
infection (can lead to ulcers in the stomach and upper part of small
intestine) and other acid-related disorders. P-CABs work by blocking
acid secretion in the stomach. The company says they work better than
standard-of-care proton pump inhibitors (PPIs) in acid-related diseases,
adding that 15-45% of GERD patients do not achieve adequate symptom
relief with PPIs.
It in-licensed the rights to vonoprazan in the U.S., Europe and Canada from Takeda Pharmaceutical Company (NYSE:TAK) in May. Two Phase 3 GERD studies should launch this quarter.
2019 Financials (6 mo.): Operating Expenses: $84.2M (+999%); Net Loss: ($89.0M) (-999%); Cash Burn: ($6.0M) (-999%).
https://seekingalpha.com/news/3507088-phathom-pharmaceuticals-readies-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.